On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the January 2023 CRG meeting.
Actions in this consultation include:
- Avatrombopag added to formulary as a RED drug for primary chronic immune thrombocytopenia.
- Esketamine nasal spray for treatment-resistant depression added to the DNP list.
All links to MHRA drug safety updates will be added to formulary as appropriate.
To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 6th March 2023.